CHMP says no to Amgen’s osteoporosis drug Evenity

Three drugmakers challenge Trump’s price disclosure ruling

Amgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will require them to disclose medicine list prices in direct-to-consumer (DTC) television ads.

FDA approves Herceptin biosimilar as US patent expires

The FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer blockbuster’s patent expiry.

Amgen offers $167m for drug discovery biotech Nuevolution

Amgen has agreed to buy Swedish biotech Nuevolution for around $167 million to boost its drug pipeline after an R&D collaboration showed promise.

Hear from Amgen speaking at the 4th Pre-filled Syringes West...

Pre-filled Syringes WC - workshop

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.